CardiacSense
CardiacSense is an Israeli medical device company that develops an FDA-cleared, CE-marked wearable wristwatch using PPG-based sensor fusion for continuous atrial fibrillation detection, cuffless blood pressure monitoring, and multi-vital sign tracking, sold to hospitals, physicians, insurers, and patients across 16+ countries via regional distributors and a recurring cloud subscription.
- Company typePrivate
- Founded2012
- HeadquartersCaesarea, Israel
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What CardiacSense does
CardiacSense is an Israel-based medical device company founded in 2012 and headquartered in Caesarea, developing a clinically validated wearable wristwatch (CS Watch) for continuous 24/7 cardiac monitoring. Its proprietary technology integrates photoplethysmography (PPG) with motion, temperature, and pressure sensors to detect atrial fibrillation and other arrhythmias, monitor cuffless blood pressure, respiratory rate, SpO2, and body temperature. Clinical performance is documented at 99.1% sensitivity and 0.6% false detection rate for AF detection, with FDA 510(k) clearance (January 2023), CE Mark (February 2021), Israeli Ministry of Health approval (August 2020), and ISO 13485:2016 certification.
The company operates a dual revenue model combining one-time hardware sales of the medical watch with recurring monthly cloud-based monitoring subscriptions that feed physician portals, monthly reports, and EMR integration. Commercialization is executed through a global distributor network covering 16+ countries, with a $32.4 million India contract (Xplore Lifestyle) and approximately $30 million in total pre-launch distribution commitments serving as the most visible commercial signal. In 2024, CardiacSense extended its offering with a System On Module (SOM) chip for OEM licensing, enabling its IP to be embedded in third-party wearables. Customers include hospitals, cardiologists, electrophysiologists, primary care physicians, insurers/HMOs, clinical research organizations, and individual patients with chronic cardiac or hypertension conditions.
CardiacSense firmographics
Firmographics- Name
- CardiacSense
- Legal name
- CardiacSense Ltd.
- Website
- https://cardiacsense.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CardiacSense is an Israeli medical device company that develops an FDA-cleared, CE-marked wearable wristwatch using PPG-based sensor fusion for continuous atrial fibrillation detection, cuffless blood pressure monitoring, and multi-vital sign tracking, sold to hospitals, physicians, insurers, and patients across 16+ countries via regional distributors and a recurring cloud subscription.
- Ownership category
- akta.pro rank
CardiacSense industry classification
Industry- Product category
- Wearable Cardiac Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)
- akta.pro secondary industries
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Cardiology Telemedicine Platforms (HLALAGAB)
Keywords
Where CardiacSense is headquartered
LocationHeadquarters
- HQ city
- Caesarea
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
CardiacSense business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Watch Sales: Revenue from sales of the CardiacSense medical wristwatch. The watch uses unique, patent-protected integrative technology of optical signals with motion, temperature, and pressure sensors to monitor patient vital body indices and transmits data directly to patients' physicians.
- Cloud-Based Monitoring Services: Monthly fee cloud-based monitoring and follow-up service enabling continuous measurement history, real-time watch connectivity, connection to external applications and service providers, and digital cloud platform for physicians and clinics. The company announced approximately $30 million in distribution agreements ahead of sales launch.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Medical Watch Device |
| Subscription | Monthly | Cloud-Based Monitoring Service |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
CardiacSense product offering
Product offeringCore offering
CardiacSense develops and sells the CS Watch, an FDA-cleared and CE-marked medical-grade wearable that continuously monitors cardiac arrhythmias (atrial fibrillation, tachycardia, bradycardia, cardiac arrest), cuffless blood pressure, heart rate, respiratory rate, SpO2, body temperature, and sleep patterns using a patent-protected combination of photoplethysmography (PPG) and motion/temperature/pressure sensors. The hardware is paired with a HIPAA- and GDPR-compliant cloud-based monitoring service that delivers real-time alerts, physician portals, monthly reports, and EMR integration, sold through a global network of 16+ regional medical-device distributors.
Product overview
CardiacSense offers a portfolio of medical-grade wearable monitoring solutions centered on the CS WATCH, a clinically-validated smartwatch providing continuous 24/7 monitoring of cardiac arrhythmias (atrial fibrillation, cardiac arrest, tachycardia, bradycardia), blood pressure, respiratory rate, SpO2, body temperature, and sleep apnea. The product line spans multiple watch generations (CS3 through CS6) with progressive capability additions. Complementing the watch is a System On Module (SOM) chip for OEM integration into third-party wearables, and a cloud-based subscription service providing data synchronization, physician portals, monthly reports, and EMR integration. The company was founded in 2012, is headquartered in Caesarea, Israel, and holds FDA, CE, and ISO 13485:2016 certifications.
Differentiator
Problem solved
Functional benefit
Products and services
- CS Watch (Medical Watch) A clinically validated, FDA-cleared and CE-marked medical-grade wearable watch providing 24/7/365 continuous monitoring of cardiac arrhythmias (atrial fibrillation, cardiac arrest, tachycardia, bradycardia), blood pressure, heart rate, respiratory rate, SpO2, body temperature, and sleep patterns. Combines PPG and ECG technologies with motion/temperature/pressure sensors and is sold to physicians, hospitals, insurers, clinical researchers, and patients.
- System On Module (SOM) Chip A miniaturized system module that integrates CardiacSense's vital-sign monitoring technology for licensing to OEM manufacturers, enabling embedding of the company's monitoring capability into third-party wearable form factors such as rings, headbands, glasses, and hats.
- Cloud-Based Monitoring Service Monthly subscription cloud platform enabling continuous health monitoring, real-time data sync between the CS Watch and physician portals, monthly patient reports, historical data storage, and integration with external applications, service providers, and EMR systems. Sold to physicians, clinics, and hospitals as the recurring-revenue complement to CS Watch hardware sales.
Quantifiable outcome
- 99% sensitivity and 99% specificity in distinguishing atrial fibrillation from sinus rhythm in clinical trials
- +4 more outcomes
Companies that use CardiacSense
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles5 records
CardiacSense technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature5 records
CardiacSense partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights6 records
CardiacSense competitors and assessment
Company assessmentEmerging players
- Withings: Withings offers connected health devices (watches, BPM Core) with ECG, AF detection, and blood pressure monitoring, overlapping with CardiacSense's multi-vital wearable strategy.
- Eko Health: Eko's AI-powered digital stethoscopes and cardiac analysis platform serve similar clinician customers with continuous monitoring and arrhythmia detection capabilities, representing an adjacent but comparable cardiac diagnostics offering.
Direct peers
- iRhythm Technologies: iRhythm's Zio long-term continuous ECG monitoring patch competes directly with CardiacSense's wearable for arrhythmia detection use cases, targeting similar cardiologist customers with continuous monitoring services.
- Preventice Solutions (Boston Scientific): Preventice (now part of Boston Scientific) offers BodyGuardian remote cardiac monitoring solutions directly competing with CardiacSense for hospital telemetry and remote patient monitoring contracts.
- AliveCor: AliveCor's KardiaMobile and KardiaBand deliver consumer and clinical-grade ECG/AF detection on smartphones and Apple Watch, directly competing with CardiacSense's watch-based AF detection offering for both patients and physicians.
Broad incumbents
- Fitbit (Google): Fitbit's heart rhythm assessment features and integration with Google's health platform provide a consumer-scale wearable competitor targeting AF detection and health monitoring use cases.
- Boston Scientific: Boston Scientific is a major cardiology device incumbent (and CardiacSense Chairman Mike Berman's former employer); its broader portfolio of cardiac diagnostics and remote monitoring overlaps with CardiacSense's clinical focus.
- Apple: Apple Watch's built-in ECG and AF detection features represent the dominant consumer wearable cardiac monitoring platform, with massive scale advantages that pressure specialized entrants like CardiacSense on price and brand.
- Omron Healthcare: Omron is a global leader in clinical and consumer blood pressure monitoring devices; their expansion into connected wearables and cuffless BP (HeartGuide) directly competes with CardiacSense's hypertension focus.
- Philips (BioTel Care/Remote Cardiac Monitoring): Philips (including acquired BioTelemetry) is a global leader in clinical-grade remote cardiac monitoring, offering Mobile Cardiac Telemetry and Holter services that overlap with CardiacSense's hospital/physician targeting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
CardiacSense social profiles
Digital presenceCardiacSense compliance and trust
Trust signalCompliance5 records
CardiacSense financial estimates
Financial estimateRevenue estimate
Valuation estimate
CardiacSense leadership team
Management profileNumber of profiles
Profiles14 records
CardiacSense funding detail
Funding detailFunding overview
Funding rounds11 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CardiacSense M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CardiacSense
What does CardiacSense do?
CardiacSense develops and sells the CS Watch, an FDA-cleared and CE-marked medical-grade wearable that continuously monitors cardiac arrhythmias (atrial fibrillation, tachycardia, bradycardia, cardiac arrest), cuffless blood pressure, heart rate, respiratory rate, SpO2, body temperature, and sleep patterns using a patent-protected combination of photoplethysmography (PPG) and motion/temperature/pressure sensors. The hardware is paired with a HIPAA- and GDPR-compliant cloud-based monitoring service that delivers real-time alerts, physician portals, monthly reports, and EMR integration, sold through a global network of 16+ regional medical-device distributors.
Is CardiacSense a public or private company?
CardiacSense is a private company. It is classified as venture growth investor backed and is currently operating.
When was CardiacSense founded?
CardiacSense was founded in 2012. It employs 11 to 50 people.
Where is CardiacSense based?
CardiacSense is headquartered in Caesarea, Israel, in the Middle East region.
How does CardiacSense make money?
Two revenue lines are on record. Medical Watch Sales are the primary driver. The others are cloud-Based Monitoring Services.
Who are CardiacSense's main competitors?
Emerging players on record are Withings and Eko Health. Direct peers are iRhythm Technologies, Preventice Solutions (Boston Scientific) and AliveCor. Broad incumbents are Fitbit (Google), Boston Scientific, Apple, Omron Healthcare and Philips (BioTel Care/Remote Cardiac Monitoring).
Does CardiacSense have an API?
No public API is recorded for CardiacSense.
What industry is CardiacSense in?
CardiacSense's product category is Wearable Cardiac Monitoring Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders). Its NAICS code is 334510 and its SIC code is 3845.